Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Place of Percutaneous Fistula Devices in Contemporary Management of Vascular Access.

Wasse H.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):938-940. doi: 10.2215/CJN.00980119. Epub 2019 Apr 1. No abstract available.

PMID:
30936152
2.

Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients.

Thamer M, Lee TC, Wasse H, Glickman MH, Qian J, Gottlieb D, Toner S, Pflederer TA.

Am J Kidney Dis. 2018 Jul;72(1):10-18. doi: 10.1053/j.ajkd.2018.01.034. Epub 2018 Mar 28.

3.

Clinical Trial End Points for Hemodialysis Vascular Access: Background, Rationale, and Definitions.

Shenoy S, Allon M, Beathard G, Brouwer-Maier D, Dember LM, Glickman M, Lee C, Litchfield T, Lok C, Huber T, Roy-Chaudhury P, Work J, West M, Wasse H.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):490-494. doi: 10.2215/CJN.13321216. Epub 2018 Feb 27. No abstract available.

4.

Chronic Central Venous Access: From Research Consensus Panel to National Multistakeholder Initiative.

Baskin KM, Durack JC, Abu-Elmagd K, Doellman D, Drews BB, Journeycake JM, Kocoshis SA, McLennan G, Rupp SM, Towbin RB, Wasse H, Mermel LA, Toomay SM, Camillus JC, Ahrar K, White SB.

J Vasc Interv Radiol. 2018 Apr;29(4):461-469. doi: 10.1016/j.jvir.2017.12.009. Epub 2018 Feb 15. No abstract available.

PMID:
29456059
5.

International Differences in the Location and Use of Arteriovenous Accesses Created for Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Pisoni RL, Zepel L, Fluck R, Lok CE, Kawanishi H, Süleymanlar G, Wasse H, Tentori F, Zee J, Li Y, Schaubel D, Burke S, Robinson B.

Am J Kidney Dis. 2018 Apr;71(4):469-478. doi: 10.1053/j.ajkd.2017.09.012. Epub 2017 Dec 1.

6.

Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.

Beathard GA, Lok CE, Glickman MH, Al-Jaishi AA, Bednarski D, Cull DL, Lawson JH, Lee TC, Niyyar VD, Syracuse D, Trerotola SO, Roy-Chaudhury P, Shenoy S, Underwood M, Wasse H, Woo K, Yuo TH, Huber TS.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):501-512. doi: 10.2215/CJN.11531116. Epub 2017 Jul 20.

7.

Recommended Clinical Trial End Points for Dialysis Catheters.

Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Chand DH, Easom AM, Mermel L, Mokrzycki MH, Patel PR, Roy-Chaudhury P, Shenoy S, Valentini RP, Wasse H.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):495-500. doi: 10.2215/CJN.12011116. Epub 2017 Jul 20.

8.

Vessel Mapping for Dialysis Access Planning.

Niyyar VD, Wasse H.

Semin Dial. 2017 Jul;30(4):305-308. doi: 10.1111/sdi.12594. Epub 2017 Apr 5. Review.

PMID:
28382736
9.

Cerebral hyperperfusion and other consequences of hemodialysis central vein catheters.

Wasse H.

J Vasc Access. 2017 Mar 6;18(Suppl. 1):82-83. doi: 10.5301/jva.5000689. Epub 2017 Mar 5. Review.

PMID:
28297066
10.

Factors related to patient selection and initiation of peritoneal dialysis.

Wasse H.

J Vasc Access. 2017 Mar 6;18(Suppl. 1):39-40. doi: 10.5301/jva.5000687. Epub 2017 Mar 5. Review.

PMID:
28297056
11.

Falls among hemodialysis patients: potential opportunities for prevention?

Kutner NG, Zhang R, Huang Y, Wasse H.

Clin Kidney J. 2014 Jun;7(3):257-63. doi: 10.1093/ckj/sfu034. Epub 2014 Apr 15.

12.

Vitamin D therapy in kidney disease: more vitamin D is necessary.

Tangpricha V, Wasse H.

Am J Kidney Dis. 2014 Nov;64(5):667-9. doi: 10.1053/j.ajkd.2014.08.004. No abstract available.

PMID:
25343995
13.

Gait speed and hospitalization among ambulatory hemodialysis patients: USRDS special study data.

Kutner NG, Zhang R, Huang Y, Wasse H.

World J Nephrol. 2014 Aug 6;3(3):101-6. doi: 10.5527/wjn.v3.i3.101.

14.

Health status as a potential mediator of the association between hemodialysis vascular access and mortality.

Grubbs V, Wasse H, Vittinghoff E, Grimes BA, Johansen KL.

Nephrol Dial Transplant. 2014 Apr;29(4):892-8. doi: 10.1093/ndt/gft438. Epub 2013 Nov 13.

15.

Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study.

Wasse H, Huang R, Long Q, Zhao Y, Singapuri S, McKinnon W, Skardasis G, Tangpricha V.

J Vasc Access. 2014 Mar-Apr;15(2):88-94. doi: 10.5301/jva.5000187. Epub 2013 Oct 7.

16.

Impact of Mast Cell Chymase on Renal Disease Progression.

Wasse H, Naqvi N, Husain A.

Curr Hypertens Rev. 2012 Feb 1;8(1):15-23.

17.

Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease.

Alvarez JA, Zughaier SM, Law J, Hao L, Wasse H, Ziegler TR, Tangpricha V.

Eur J Clin Nutr. 2013 Mar;67(3):264-9. doi: 10.1038/ejcn.2012.217. Epub 2013 Jan 30. Erratum in: Eur J Clin Nutr. 2013 Nov;67(11):1228.

18.

High-output heart failure: how to define it, when to treat it, and how to treat it.

Wasse H, Singapuri MS.

Semin Nephrol. 2012 Nov;32(6):551-7. doi: 10.1016/j.semnephrol.2012.10.006. Review.

PMID:
23217335
19.

Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients.

Wasse H, Cardarelli F, De Staercke C, Hooper WC, Long Q.

Nephrol Dial Transplant. 2013 Apr;28(4):991-7. doi: 10.1093/ndt/gfs349. Epub 2012 Oct 22.

20.

Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review.

Alvarez J, Wasse H, Tangpricha V.

Dermatoendocrinol. 2012 Apr 1;4(2):118-27. doi: 10.4161/derm.20014.

21.

Cardiovascular implantable electronic device leads in CKD and ESRD patients: review and recommendations for practice.

Saad TF, Hentschel DM, Koplan B, Wasse H, Asif A, Patel DV, Salman L, Carrillo R, Hoggard J; ASDIN Clinical Practice Committee Workgroup.

Semin Dial. 2013 Jan-Feb;26(1):114-23. doi: 10.1111/j.1525-139X.2012.01103.x. Epub 2012 Aug 15. Review.

PMID:
22891983
22.

High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.

Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K, Wasse H, Gutiérrez OM, Ziegler TR, Tangpricha V.

Am J Clin Nutr. 2012 Sep;96(3):672-9. doi: 10.3945/ajcn.112.040642. Epub 2012 Aug 1.

23.

Proteinuria among patients with chronic kidney disease: a performance measure for improving patient outcomes.

Thorp ML, Smith DH, Johnson ES, Vupputuri S, Weiss JW, Petrik AF, Yang X, Levey AS, Wasse H, Muoneke R, Snyder SR.

Jt Comm J Qual Patient Saf. 2012 Jun;38(6):277-82. Review.

PMID:
22737779
24.

ESRD patients using permanent vascular access report greater physical activity compared with catheter users.

Wasse H, Zhang R, Johansen KL, Kutner N.

Int Urol Nephrol. 2013 Feb;45(1):199-205. doi: 10.1007/s11255-012-0137-9. Epub 2012 Feb 17.

25.

Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis.

Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V.

Am J Clin Nutr. 2012 Feb;95(2):522-8. doi: 10.3945/ajcn.111.025502. Epub 2012 Jan 11.

26.

Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients.

Wasse H, Huang R, Naqvi N, Smith E, Wang D, Husain A.

J Vasc Access. 2012 Apr-Jun;13(2):168-74. doi: 10.5301/jva.5000024.

27.

Increased plasma chymase concentration and mast cell chymase expression in venous neointimal lesions of patients with CKD and ESRD.

Wasse H, Rivera AA, Huang R, Martinson DE, Long Q, McKinnon W, Naqvi N, Husain A.

Semin Dial. 2011 Nov-Dec;24(6):688-93. doi: 10.1111/j.1525-139X.2011.00921.x. Epub 2011 Jul 22.

28.

25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients.

Wasse H, Cardarelli F, De Staercke C, Hooper C, Veledar E, Guessous I.

BMC Nephrol. 2011 May 22;12:24. doi: 10.1186/1471-2369-12-24.

29.

Achieving the goal of the Fistula First breakthrough initiative for prevalent maintenance hemodialysis patients.

Lynch JR, Wasse H, Armistead NC, McClellan WM.

Am J Kidney Dis. 2011 Jan;57(1):78-89. doi: 10.1053/j.ajkd.2010.08.028. Epub 2010 Nov 30.

30.

Patient awareness and initiation of peritoneal dialysis.

Kutner NG, Zhang R, Huang Y, Wasse H.

Arch Intern Med. 2011 Jan 24;171(2):119-24. doi: 10.1001/archinternmed.2010.361. Epub 2010 Sep 27.

PMID:
20876396
31.

Geographic concentration of poverty and arteriovenous fistula use among ESRD patients.

McClellan WM, Wasse H, McClellan AC, Holt J, Krisher J, Waller LA.

J Am Soc Nephrol. 2010 Oct;21(10):1776-82. doi: 10.1681/ASN.2009121235. Epub 2010 Aug 5.

32.

Racial and gender differences in arteriovenous fistula use among incident hemodialysis patients.

Wasse H, Hopson SD, McClellan W.

Am J Nephrol. 2010;32(3):234-41. doi: 10.1159/000318152. Epub 2010 Jul 27.

33.

Low documentation of chronic kidney disease among high-risk patients in a managed care population: a retrospective cohort study.

Guessous I, McClellan W, Vupputuri S, Wasse H.

BMC Nephrol. 2009 Sep 16;10:25. doi: 10.1186/1471-2369-10-25.

34.

Vascular mapping: does it help to maximize fistulae placement?

Niyyar VD, Wasse H.

Adv Chronic Kidney Dis. 2009 Sep;16(5):316-20. doi: 10.1053/j.ackd.2009.06.007. Review.

35.

Increasing physician knowledge about the diagnosis and management of CKD: how can we help primary care providers?

Wasse H, McClellan WM.

Am J Kidney Dis. 2009 Aug;54(2):187-90. doi: 10.1053/j.ajkd.2009.05.002. No abstract available.

PMID:
19619840
36.

Neighborhood poverty and racial disparities in kidney transplant waitlisting.

Patzer RE, Amaral S, Wasse H, Volkova N, Kleinbaum D, McClellan WM.

J Am Soc Nephrol. 2009 Jun;20(6):1333-40. doi: 10.1681/ASN.2008030335. Epub 2009 Apr 1.

37.

Treatment center and geographic variability in pre-ESRD care associate with increased mortality.

McClellan WM, Wasse H, McClellan AC, Kipp A, Waller LA, Rocco MV.

J Am Soc Nephrol. 2009 May;20(5):1078-85. doi: 10.1681/ASN.2008060624. Epub 2009 Mar 25.

38.

Catheter-related mortality among ESRD patients.

Wasse H.

Semin Dial. 2008 Nov-Dec;21(6):547-9. doi: 10.1111/j.1525-139X.2008.00500.x. Epub 2008 Sep 24.

39.

Arteriovenous fistula use is associated with lower cardiovascular mortality compared with catheter use among ESRD patients.

Wasse H, Speckman RA, McClellan WM.

Semin Dial. 2008 Sep-Oct;21(5):483-9. doi: 10.1111/j.1525-139X.2008.00467.x. Epub 2008 Aug 29.

40.

Predictors of central venous catheter use at the initiation of hemodialysis.

Wasse H, Speckman RA, Frankenfield DL, Rocco MV, McClellan WM.

Semin Dial. 2008 Jul-Aug;21(4):346-51. doi: 10.1111/j.1525-139X.2008.00447.x. Epub 2008 Jun 28.

41.

How I do it: thrombosed arteriovenous graft resulting from a crushed stent in a nonambulatory hemodialysis patient.

Wasse H.

Semin Dial. 2008 Mar-Apr;21(2):178-9. doi: 10.1111/j.1525-139X.2007.00398.x. Epub 2008 Jan 23. No abstract available.

42.
43.

Association of initial hemodialysis vascular access with patient-reported health status and quality of life.

Wasse H, Kutner N, Zhang R, Huang Y.

Clin J Am Soc Nephrol. 2007 Jul;2(4):708-14. Epub 2007 May 18.

44.

Predictors of delayed transition from central venous catheter use to permanent vascular access among ESRD patients.

Wasse H, Speckman RA, Frankenfield DL, Rocco MV, McClellan WM.

Am J Kidney Dis. 2007 Feb;49(2):276-83.

45.
46.

Risk for progression to ESRD: Further evidence from population-based studies.

Wasse H, McClellan W.

J Am Soc Nephrol. 2006 Aug;17(8):2092-3. Epub 2006 Jul 12. No abstract available.

47.

Parathyroidectomy rates among United States dialysis patients: 1990-1999.

Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO.

Kidney Int. 2004 Jan;65(1):282-8.

48.

Risk factors for incident stroke among patients with end-stage renal disease.

Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO.

J Am Soc Nephrol. 2003 Oct;14(10):2623-31.

49.

Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients.

Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO.

Kidney Int. 2003 Oct;64(4):1455-61.

50.

Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.

Zager RA, Johnson AC, Hanson SY, Wasse H.

Am J Kidney Dis. 2002 Jul;40(1):90-103.

PMID:
12087566

Supplemental Content

Support Center